206 related articles for article (PubMed ID: 38594285)
1. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
[TBL] [Abstract][Full Text] [Related]
2. Impact of the International Consensus Classification of myelodysplastic syndromes.
Zhang Y; Wu J; Xu Z; Qin T; Qu S; Pan L; Wang H; Sun Q; Li C; Jia Y; Cai W; Yan X; Gong J; Gao Q; Li B; Gale RP; Xiao Z
Br J Haematol; 2023 May; 201(3):443-448. PubMed ID: 36575970
[TBL] [Abstract][Full Text] [Related]
3. The International Consensus Classification of myelodysplastic syndromes and related entities.
Hasserjian RP; Orazi A; Orfao A; Rozman M; Wang SA
Virchows Arch; 2023 Jan; 482(1):39-51. PubMed ID: 36287260
[TBL] [Abstract][Full Text] [Related]
4. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
[TBL] [Abstract][Full Text] [Related]
5. The clinical, molecular, and prognostic features of the 2022 WHO and ICC classification systems for myelodysplastic neoplasms.
Khanna V; Lu R; Kumar J; Molina A; Stehr H; Spiteri E; Spinner M; Silva O; Fernandez-Pol S; Tan B; Greenberg PL
Leuk Res; 2024 Jan; 136():107433. PubMed ID: 38154193
[TBL] [Abstract][Full Text] [Related]
6. Implications of the 5
Lee C; Kim HN; Kwon JA; Yoon SY; Jeon MJ; Yu ES; Kim DS; Choi CW; Yoon J
Ann Lab Med; 2023 Sep; 43(5):503-507. PubMed ID: 37080752
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract][Full Text] [Related]
8. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
9. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
10. Reporting bone marrow biopsies for myelodysplastic neoplasms and acute myeloid leukaemia incorporating WHO 5th edition and ICC 2022 classification systems: ALLG/RCPA joint committee consensus recommendations.
Ng AP; Adams R; Tiong IS; Seymour L; Talaulikar D; Palfreyman E; Enjeti A; Tate C
Pathology; 2024 Jun; 56(4):459-467. PubMed ID: 38580613
[TBL] [Abstract][Full Text] [Related]
11. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.
Lee WH; Tsai MT; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Liu MC; Yang YT; Chen JC; Tang JL; Sun HI; Chuang YK; Lin LI; Chou WC; Lin CC; Hou HA; Tien HF
Blood Cancer J; 2023 Aug; 13(1):120. PubMed ID: 37558665
[TBL] [Abstract][Full Text] [Related]
12. Morphologic Characteristics of Myelodysplastic Syndromes.
Yuen LD; Hasserjian RP
Clin Lab Med; 2023 Dec; 43(4):577-596. PubMed ID: 37865504
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogénétique hématologique (GFCH).
Auger N; Douet-Guilbert N; Quessada J; Theisen O; Lafage-Pochitaloff M; Troadec MB
Curr Res Transl Med; 2023; 71(4):103409. PubMed ID: 38091642
[TBL] [Abstract][Full Text] [Related]
14. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
Bruehl FK; Osman MM; Chen D; Dalland JC
J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
16. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
17. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
18. Application of the International Consensus Classification and World Health Organization 5th edition classification to a series of myeloid neoplasms.
Chopra S; Bailey NG
Am J Clin Pathol; 2023 Dec; 160(6):566-570. PubMed ID: 37587830
[TBL] [Abstract][Full Text] [Related]
19. The International Consensus Classification (ICC) of hematologic neoplasms with germline predisposition, pediatric myelodysplastic syndrome, and juvenile myelomonocytic leukemia.
Rudelius M; Weinberg OK; Niemeyer CM; Shimamura A; Calvo KR
Virchows Arch; 2023 Jan; 482(1):113-130. PubMed ID: 36445482
[TBL] [Abstract][Full Text] [Related]
20. Molecular landscape of myelodysplastic neoplasms in disease classification and prognostication.
Maggioni G; Della Porta MG
Curr Opin Hematol; 2023 Mar; 30(2):30-37. PubMed ID: 36728601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
